Lupin Ltd
LUPINLupin Ltd
LUPINPrice Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
42.16 | 6.43 | 0.45% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
44.11 | 6.27 | 0.57% |
Forecast & Ratings
Detailed Forecastfrom 29 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Lupin Limited is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world.
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Zydus Lifesciences Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 14,445.63 | 17,482.14 | 15,950.42 | 15,095.78 | 15,992.56 | 15,300.58 | 16,615.93 | 16,792.57 | 20,130.99 | 20,132.67 | ||||||||||
Raw Materials | 4,778.49 | 5,339.31 | 5,111.62 | 5,150.54 | 5,422.05 | 5,847.10 | 6,679.56 | 6,626.03 | 16,200.30 | 16,201.98 | ||||||||||
Power & Fuel Cost | 381.27 | 377.86 | 433.88 | 442.28 | 443.17 | 414.48 | 443.96 | 479.68 | ||||||||||||
Employee Cost | 2,141.62 | 2,849.52 | 2,864.71 | 2,770.17 | 2,986.84 | 2,825.90 | 2,989.30 | 3,087.15 | ||||||||||||
Selling & Administrative Expenses | 2,369.26 | 2,377.17 | 2,386.87 | 2,513.07 | 2,541.16 | 2,230.63 | 2,490.56 | 2,755.54 | ||||||||||||
Operating & Other expenses | 899.55 | 1,930.38 | 3,316.31 | 1,567.76 | 2,378.81 | 1,277.97 | 3,583.28 | 1,972.69 | ||||||||||||
EBITDA | 3,875.44 | 4,607.90 | 1,837.03 | 2,651.96 | 2,220.53 | 2,704.50 | 429.27 | 1,871.48 | 3,930.69 | 3,930.69 | ||||||||||
Depreciation/Amortization | 487.13 | 912.23 | 1,085.87 | 846.05 | 970.22 | 887.41 | 1,658.71 | 880.69 | 1,196.81 | 1,196.81 | ||||||||||
PBIT | 3,388.31 | 3,695.67 | 751.16 | 1,805.91 | 1,250.31 | 1,817.09 | -1,229.44 | 990.79 | 2,733.88 | 2,733.88 | ||||||||||
Interest & Other Items | 59.47 | 152.53 | 204.35 | 302.49 | 362.98 | 140.64 | 142.77 | 274.30 | 311.61 | 311.61 | ||||||||||
PBT | 3,328.84 | 3,543.14 | 546.81 | 1,503.42 | 887.33 | 1,676.45 | -1,372.21 | 716.49 | 2,422.27 | 2,422.27 | ||||||||||
Taxes & Other Items | 1,068.10 | 985.68 | 295.55 | 896.87 | 1,156.72 | 459.92 | 155.83 | 286.41 | 507.79 | 507.79 | ||||||||||
Net Income | 2,260.74 | 2,557.46 | 251.26 | 606.55 | -269.39 | 1,216.53 | -1,528.04 | 430.08 | 1,914.48 | 1,914.48 | ||||||||||
EPS | 50.23 | 56.70 | 5.56 | 13.41 | -5.95 | 26.83 | -33.65 | 9.46 | 42.05 | 42.08 | ||||||||||
DPS | 7.50 | 7.50 | 5.00 | 5.00 | 6.00 | 6.50 | 4.00 | 4.00 | 8.00 | 4.00 | ||||||||||
Payout ratio | 0.15 | 0.13 | 0.90 | 0.37 | — | 0.24 | — | 0.42 | 0.19 | 0.10 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Lupin Ltd | 42.16 | 6.43 | 0.45% |
Sun Pharmaceutical Industries Ltd | 39.30 | 6.34 | 0.86% |
Cipla Ltd | 29.58 | 5.14 | 0.86% |
Zydus Lifesciences Ltd | 30.31 | 5.94 | 0.26% |
Price Comparison
Compare LUPIN with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Increased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has increased by 2.17%
Shareholding Pattern
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Shareholding History
Mutual Funds Holding Trend
Decreased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has decreased by 2.11%
Top 5 Mutual Funds holding Lupin Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
HDFC Balanced Advantage Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.1456% | Percentage of the fund’s portfolio invested in the stock 1.06% | Change in the portfolio weight of the stock over the last 3 months -0.13% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 20/288 (-1) |
ICICI Prudential Value Discovery Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.8131% | Percentage of the fund’s portfolio invested in the stock 1.53% | Change in the portfolio weight of the stock over the last 3 months -0.12% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 50/90 (-1) |
ICICI Prudential Bluechip Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.7020% | Percentage of the fund’s portfolio invested in the stock 1.02% | Change in the portfolio weight of the stock over the last 3 months -0.29% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 24/83 (-1) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Trend In Dividends
LUPIN has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Current dividend yield is 0.49%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹4.90 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 14, 2023
Dividend/Share
₹4.00
Ex DateEx Date
Jul 14, 2023
Cash Dividend
Ex DateEx DateJul 14, 2022
Dividend/Share
₹4.00
Ex DateEx Date
Jul 14, 2022
Cash Dividend
Ex DateEx DateJul 27, 2021
Dividend/Share
₹6.50
Ex DateEx Date
Jul 27, 2021
Cash Dividend
Ex DateEx DateAug 3, 2020
Dividend/Share
₹6.00
Ex DateEx Date
Aug 3, 2020
Cash Dividend
Ex DateEx DateJul 29, 2019
Dividend/Share
₹5.00
Ex DateEx Date
Jul 29, 2019
News & Opinions
News Video
LIVE: Look Ahead To Tomorrow's Trade: What Are Key Events, Stocks To Watch | Markets Forward
19 hours ago•CNBC-TV18
Lupin stock hits eight-year high at Rs 1,749 on healthy earnings outlook
1 day ago•Business Standard
Lupin stock rallies 7%, hits multi-year high on healthy earnings outlook
1 day ago•Business Standard
Lupin Shares Rise Over 6% After Kotak’s Double Upgrade To ‘Add’; Check Target Price - News18
1 day ago•News18
Stocks to buy and sell on July 4: Bhel, Lupin, Firstsource Solutions
1 day ago•Business Standard
News Video
Lupin Share News | Long Term के लिए Stock को Portfolio में रखने से कितना फायदा? | Women Traders
3 days ago•CNBC Awaaz.
Lupin to pay fine of Euro 40 million to European Commission
1 week ago•Business Standard
Stocks to watch on June 24: Sun Pharma, Cipla, Lupin, Vedanta, Tata Steel
1 week ago•Business Standard
Lupin, Eugia recall products from US over manufacturing issues: USFDA
1 week ago•Business Standard
Lupin appoints Abdelaziz Toumi as CEO of newly established subsidiary LMS
2 weeks ago•Business Standard
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 5.93%, vs industry avg of 9%
Decreasing Market Share
Over the last 5 years, market share decreased from 6.81% to 5.64%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 25.85%, vs industry avg of 15.09%